Aller au contenu principal
Profil bibliographique

Oğuz Kara

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

23Publications signalées
108Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Breast Cancer Treatment StudiesGlobal Cancer Incidence and ScreeningGastric Cancer Management and OutcomesHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies

Les publications récentes

2024 article OpenAlex

Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Hasan Çağrı Yıldırım, Ertuğrul Bayram, Elvin Chalabiyev, Nargız Majidova et autres

Non-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial data is limited and treatment options generally follow those of clear cell …

tr, in, us, ag (code pays fourni par la source)

4 citations Journal of Chemotherapy
Accès ouvert 2024 article OpenAlex

Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

Hasan Çağrı Yıldırım, Caner Kapar, Barış Köksal, Mustafa Seyyar et autres

The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the MONALEESA-7 study, and data on the effectiveness of palbociclib is limited. Data …

tr (code pays fourni par la source)

8 citations Journal of Chemotherapy
Accès ouvert 2019 article OpenAlex

Effect of neoadjuvant chemotherapy on ER, PR, c-erb2, VEGF and Ki-67 in patients with locally advanced breast cancer

Ahmet Gökhan Sarıtaş, Orçun Yalav, Yalçın Kekeç, Gürhan Sakman et autres

Purpose: The aim of this study is aimed to demonstrate the changes in the tumor diameter and expressions of vascular endothelial growth factor (VEGF), estrogen receptor (ER), progesterone receptor (PR), Ki-67, and Cerb-B2 status after neoadjuvant chemotherapy in the patients with locally …

tr (code pays fourni par la source)

3 citations Çukurova medical journal (Online)/Çukurova medical journal
2018 conference-abstract OpenAlex

Bifidobacterium with mycosporin-like amino acid: A new model for oncogenesis.

Fatih Köse, Hüseyin Sancar Bozkurt, Cemile Karadeniz, Oğuz Kara

e24204 Background: The genus Bifidobacterium considered the gastrointestinal microbiota dominant once has an important role on immunologic,oncological and metabolic homeostasis of the host. Mycosporin-like Amino Acids (MAAs) had prebiotic effects and they modulated host immunity by regulating the proliferation and differentiation of …

tr (code pays fourni par la source)

0 citations Journal of Clinical Oncology
Accès ouvert 2018 article OpenAlex

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia

Alper Sevinc, Metin Özkan, Ahmet Özet, Faysal Dane et autres

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim in patients with chemotherapy-induced neutropenia. Patients and methods: This multicenter, observational study was conducted at 14 centers. The study included 337 patients experiencing neutropenia under chemotherapy. Patients were given either …

tr (code pays fourni par la source)

1 citation OncoTargets and Therapy
2017 conference-abstract OpenAlex

Outcomes of Turkish National Breast Cancer Registry.

Saadettin Kılıçkap, Mahmut Gümüş, Doğan Uncu, Metin Özkan et autres

Background: The aim of this registry was to collect demographic, diagnostic, treatment, and outcome information about Turkish patients with breast cancer (BC). Methods: It was designed as a multicenter, cross-sectional, non-interventional study conducted on new and previously diagnosed BC cases applied to …

tr (code pays fourni par la source)

3 citations Journal of Clinical Oncology
2017 conference-abstract OpenAlex

Characteristics of Turkish colorectal cancer patients and bevacizumab preference.

İrfan Çiçin, Mahmut Gümüş, Doğan Uncu, Metin Özkan et autres

e15055 Background: The aim of this registry was to collect demographic, diagnostic, treatment, and outcome information about Turkish patients with colorectal cancer (CRC). Methods: It was designed as a multicenter, cross-sectional, non-interventional study conducted on new and previously diagnosed CRC cases applied …

tr (code pays fourni par la source)

0 citations Journal of Clinical Oncology
2015 conference-abstract OpenAlex

Turkish National Gastric Cancer Registry.

Süleyman Buyukberber, Esra Dumanli, Doğan Uncu, Metin Özkan et autres

e12645 Background: Gastric cancer (GC) remains a common malignancy in Turkey despite its decreasing incidence in recent years. Studies investigating the clinical and biologic features of gastric cancer in Turkey are small retrospective case series providing limited information. We initiated a Turkish …

tr (code pays fourni par la source)

0 citations Journal of Clinical Oncology
2015 conference-abstract OpenAlex

Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry.

Saadettin Kılıçkap, Kadri Altundağ, Esra Dumanli, Mahmut Gümüş et autres

e12656 Background: Breast cancer (BC) is the most common cancer in women in Turkey. Presumed differences in patterns of BC presentation in pts from various geographical regions of Turkey have not been studied. We aimed to define differences in clinical and pathological …

tr (code pays fourni par la source)

0 citations Journal of Clinical Oncology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.